Stock GILD GILEAD SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Gilead Sciences, Inc.

Equities

GILD

US3755581036

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-16 pm EDT 		5-day change 1st Jan Change
67.31 USD -0.65% Intraday chart for Gilead Sciences, Inc. -3.76% -16.91%
Apr. 15 Goldman Sachs Adjusts Gilead Sciences Price Target to $73 From $76 MT
Apr. 10 Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Goldman Sachs Adjusts Gilead Sciences Price Target to $73 From $76
MT
Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP
CI
Morgan Stanley Cuts Price Target on Gilead Sciences to $80 From $83, Keeps Equalweight Rating
MT
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
BU
Nurix Therapeutics, Gilead Sciences Extend Research Collaboration By 2 Years
MT
Nurix Therapeutics, Gilead Sciences Extend Strategic Collaboration
DJ
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
CI
Sector Update: Health Care Stocks Slide Late Afternoon
MT
Top Midday Gainers
MT
Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures
MT
Top Premarket Gainers
MT
Gilead Sciences Files a Definitive Proxy Statement
CI
Gilead Sciences Files a Definitive Proxy Statement
CI
Gilead Sciences Files a Definitive Proxy Statement
CI
Gilead Sciences Inc Receives a Shareholder Proposal from David Bahnsen
CI
Gilead Sciences Inc Receives a Shareholder Proposal from John Chevedden
CI
Gilead Sciences Inc Receives a Shareholder Proposal from Jing Zhao
CI
Xilio Shares Take Flight Premarket After Gilead Deal
DJ
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall
MT
Gilead Says FDA Approves New Drug Application for Potential Hep-B Treatment for Smaller Children
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GILD Stock
  4. News Gilead Sciences, Inc.